Gilead Sciences raised its quarterly dividend to $0.82 per share in July 2026, and on paper the math looks solid. The company generated $10 billion in free cash flow last year and paid out $4 billion in dividends. That is a two-to-one coverage ratio, which is the kind of cushion that income investors, particularly retirees living off quarterly checks, look for.

But the comfort of that ratio depends almost entirely on one drug holding its position for the next decade.

The drug doing all the work

Biktarvy is Gilead's dominant HIV treatment, and it is the engine behind most of that cash. Patent settlements have pushed the earliest possible generic version to April 2036, giving Gilead roughly ten years before cheaper competitors can legally enter the market and start eroding the price. In the pharmaceutical business, that kind of protected window is called a patent runway, and ten years sounds long until you consider how quickly a company's revenue picture can change when a blockbuster drug goes off-patent.

Gilead is aware of this. The company has been spending heavily to build other revenue streams before 2036 arrives. In the second quarter of 2026, it booked an $11.2 billion charge tied to three acquisitions: Arcellx, Tubulis, and Ouro Medicines. Those are bets on next-generation cancer and cell therapies. The charge is so large it produced a quarterly net loss of $10.5 billion on the official accounting.

That number looks alarming, but it reflects how acquisition accounting works rather than the underlying business. When a company buys experimental drug programs, accounting rules require it to expense the value of that research immediately, even if the drugs won't generate revenue for years. Strip that out, and management reported underlying earnings of $2.27 per share for the quarter, with a projected full-year range of $8.50 to $8.85.

What this means for anyone holding the stock for income

The dividend yield sits at about 2.1% based on the September 3 closing price of $151.22. That is not a high yield by income-investing standards, but the stock has risen roughly 37% over the past year, so total return investors have been well rewarded. For someone primarily watching the quarterly deposit, the relevant question is whether that $0.82 check is at risk.

For now, the honest answer is: probably not. The free cash flow coverage is genuine and wide. The patent protection on Biktarvy is locked in through 2036 by settlement, not just by expiration date, which makes it harder to challenge. And Gilead has real scale. Revenue for fiscal 2025 was $29.4 billion.

The risk is structural rather than immediate. HIV drugs are extraordinarily profitable partly because patients take them for life and partly because Gilead has faced limited competition in that specific category. If the pipeline acquisitions produce approved drugs, the company will have new revenue sources before Biktarvy faces generics. If they don't, Gilead will arrive at 2036 heavily dependent on a product whose pricing power will collapse almost overnight once generics enter.

That is the tension income investors are really pricing when they buy this stock. The dividend safety grade reported by analysts is strong today, and the cash flow to support it is real. But the underlying business is running a race against its own patent clock, and the new drugs it is buying with those $11 billion acquisition charges are the hedge against losing that race.

Ten years is enough time to build something new. It is also not very long.